WallStreetZenWallStreetZen

AnalystsMichael Okunewitch
Michael Okunewitch's Stock Forecasts

Analyst Ranking
Bottom 6%
#4356 out of 4631 analysts
Average Return
-20.23%
Win Rate
19%3 out of 16
Risk vs Reward
Poor
Good

Michael Okunewitch's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Lexaria Bioscience CorpLEXX
+215.61%$0.87$2.73
2023-07-21 -
2024-07-19
Strong Buy
Chemomab Therapeutics LtdCMMB
+37.59%$0.81$1.12
2024-05-13 -
2024-07-19
Strong Buy
Acrivon Therapeutics IncACRV
+0.14%$7.32$7.33
2023-10-05 -
2024-07-19
Strong Buy

Michael Okunewitch Analyst Color

Get additional color on Michael Okunewitch's coverage of popular stocks

Michael Okunewitch's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Chemomab Therapeutics LtdCMMB
1Strong Buy$4.00+257.14%Initiates Coverage On
2 months ago
Lexaria Bioscience CorpLEXX
2Strong Buy$12.00+339.56%Maintains
5 months ago
Dmk Pharmaceuticals CorpDMKPQ
1Strong Buy$1.50+546.55%Initiates Coverage On
8 months ago
Acrivon Therapeutics IncACRV
1Strong Buy$24.00+227.42%Initiates Coverage On
10 months ago
Anebulo Pharmaceuticals IncANEB
1Strong Buy$6.00+172.73%Initiates Coverage On
10 months ago
Kiora Pharmaceuticals IncKPRX
3Strong Buy$18.00+300.00%Maintains
a year ago
Alzamend Neuro IncALZN
1Strong Buy$225.00N/AInitiates Coverage On
a year ago
Mediwound LtdMDWD
1Strong Buy$25.00N/AInitiates Coverage On
2 years ago
Biorestorative Therapies IncBRTX
1Strong Buy$6.00N/AInitiates Coverage On
2 years ago
Hcw Biologics IncHCWB
1Strong Buy$4.00N/AInitiates Coverage On
2 years ago
Longeveron IncLGVN
1Strong Buy$140.00N/AInitiates Coverage On
2 years ago
Seqll IncSEQL
1Strong Buy$120.00N/AInitiates Coverage On
2 years ago
Atai Life Sciences NvATAI
1Strong Buy$25.00N/AInitiates Coverage On
3 years ago
Citius Pharmaceuticals IncCTXR
1Strong Buy$4.00N/AInitiates Coverage On
3 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.